Thalix 50 — Thalidomide 50 mg Capsules, 30 Capsules

Thalix-50 is supplied as hard gelatin capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

• • Active Ingredient: Thalidomide USP — 50 mg.
• • Excipients: Quantum satis (q.s.) for capsule formulation.
• • Capsule Shell: Titanium Dioxide I.P., gelatin.

Packaging Configuration: 50 mg capsules are supplied in blister packs of 10. The carton contains 3 blisters totaling 30 capsules. The box features clear pregnancy warnings and Fresenius Kabi branding[cite: 8].

Pharmacodynamics:
Thalidomide is an immunomodulatory agent with anti-angiogenic and anti-inflammatory activities. Mechanisms include suppression of tumor necrosis factor-alpha (TNF-α) production, inhibition of selectin expression, down-regulation of adhesion molecules, and inhibition of myeloma cell proliferation.

Pharmacokinetics:

• • Absorption: Slow absorption following oral administration with peak plasma concentrations ($C_{max}$) reached between 1 and 5 hours.
• • Distribution: Widely distributed into body tissues; moderate plasma protein binding.
• • Metabolism: Primarily metabolized through non-enzymatic plasma hydrolysis and hepatic pathways.
• • Elimination: Terminal half-life ($T_{1/2}$) is approximately 5 to 7 hours. Excreted mainly via renal elimination.

Thalix-50 is indicated for adult patients:

• • In combination with melphalan and prednisone for the treatment of newly diagnosed multiple myeloma in patients aged ≥65 years or those ineligible for high-dose chemotherapy.
• • For other neoplastic and immune-mediated conditions as directed by an oncologist.

Treatment with Thalix-50 must be supervised by an experienced oncologist familiar with antineoplastic agents.

Method of Administration:
For oral use. Capsules should be swallowed whole, preferably at bedtime to mitigate sedative side effects, with water. Do not break, open, or chew capsules.

Dosing Regimen:
Dose and treatment schedule are individualized based on specific protocols, combination agents, and patient tolerability.

Administration of Thalix-50 is strictly contraindicated in:

• • Pregnancy: Absolute contraindication in pregnant women and women of childbearing potential failing to comply with pregnancy prevention programs[cite: 8].
• • Lactation: Contraindicated during breastfeeding.
• • Male Patients Planning Conception: Mandatory adherence to barrier contraception guidelines during treatment and follow-up.
• • Hypersensitivity: Known hypersensitivity to thalidomide or any excipient.

Key drug interactions to consider:

• • Sedative agents (barbiturates, antipsychotics, tranquilizers, opioids, antihistamines) may potentiate drowsiness.
• • Concomitant medications associated with peripheral neuropathy or thromboembolic risk require cautious monitoring.

Pregnancy:
Thalidomide is a potent human teratogen inducing severe life-threatening birth defects. It is strictly contraindicated during pregnancy[cite: 8]. Females of reproductive potential must implement effective contraception.

Lactation:
It is unknown whether thalidomide is excreted in human milk. Breastfeeding is contraindicated during treatment.

Treatment with Thalix-50 may cause serious adverse events:

• • Peripheral Neuropathy: Numbness, tingling, paresthesia in extremities.
• • Thromboembolic Events: Increased risk of deep vein thrombosis and pulmonary embolism (especially when combined with dexamethasone).
• • Nervous System Disorders: Marked somnolence, dizziness, fatigue.
• • Skin Disorders: Rash, dry skin, rare reports of severe cutaneous reactions.
• • Hematologic Abnormalities: Neutropenia, leukopenia.

Symptoms:
Data regarding overdose are limited; expected symptoms include exaggerated adverse reactions such as severe somnolence, dizziness, and nausea.

Treatment:
No specific antidote exists. Supportive care and vital sign monitoring should be instituted.

Storage Requirements for Thalix-50:

• 🌡️ Temperature: Store below 30°C.
• ☀️ Moisture & Light Protection: Store in original package to protect from light and moisture.
• 👶 Safety: Keep out of reach of children.
• ⏳ Shelf Life: Stated on packaging. Rx-only.

To verify the authenticity of Thalix-50, inspect the following Fresenius Kabi security features[cite: 8]:

• ✅ Fresenius Kabi Logo: Corporate blue three-column symbol and "FRESENIUS KABI" wordmark in the bottom right corner[cite: 8].
• ✅ Warning Symbol: Mandatory red warning symbol depicting a crossed-out pregnant woman with the text "Not to be used by pregnant women"[cite: 8].
• ✅ Color Scheme: Orange and white package layout featuring a green "50 mg" dosage banner[cite: 8].
• ✅ Package Labeling: Clear composition data, capsule illustration, and "3 x 10 Capsules" quantity marking[cite: 8].